Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,471–1,480 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1471
- Medicine slug
- telmisartan
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 41
- Source count
- 41
- Agreement rate
- 1
- Recorded readings
0.5 to 1 hour
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 41
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 41 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a075633a-2a2a-4e88-8ede-b49a3920a16c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf8e95fa-d181-4b46-8609-497e14a73dc1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57da6ef2-2e86-4e4d-90df-73a2a8cf97f6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509cd338-24db-41d1-a115-9dc999170717 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a907a7-fad9-a860-8639-4c6136c85734 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22a318-d1f2-4788-9331-66fed71ebf38 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830741dd-3f3c-4f8e-88c6-dc112166f477 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56a72ddf-c2a2-45ce-91b1-1fcfbff52c10 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4ae8694-2af4-4acb-8634-b40c1cb6fb41 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32489e86-0432-4d74-92f6-15e7450f52fa (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beaaf383-730f-4411-b5e7-15c32b53a338 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance. 12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaed12cd-5bfe-4c98-9afc-025ed86a294f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09d31eee-cd22-4918-a889-3eb4d2969525 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77442f0b-b522-4b19-ac1f-f0ce8576f0be (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13e0919-5ee2-4855-b7c8-c8ab423769dd (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3658bc8-1524-43db-930e-66f9ac01b808 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e61c209a-4fc3-4f5c-b526-6412f0b8897c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44e810d4-cf04-41d3-bdf8-0681210a669f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:671d5a85-4146-43b4-9d7d-ca53268eb2a6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be6575f-ea8d-4cd8-a49d-3d1c93f2621a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f021f06-99df-48d1-e063-6394a90a8d0f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6da5155-9c26-46bb-bc0f-ece4ea21405f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91215664-6e19-4e04-9ae7-ab5664799426 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d45da80a-58c3-4461-adf6-a85531c09eb8 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ded796-3555-4476-8b37-0cdc88d7594a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:353fcb30-2fa7-4ff1-8a18-26f3ec279d00 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fef6532d-438a-435e-a61f-216dd8551339 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:963e9245-ec7a-4bf6-9fc0-80f54e3657f0 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c55e4fe1-f04d-4995-a706-9f432fde57e4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5743c58e-deab-ac93-e063-6294a90ac1eb (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2deff49-b75e-4aaa-8114-d5ea1e3a94a5 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd2b0604-f887-40d9-9109-dafcc9987e4e (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a020e2a7-d1e7-8ae0-e053-2995a90abad3 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71902893-55da-4286-8b25-b528641489ef (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance. 12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:593a53a4-91bc-4e4a-aeff-08fc2efe3dd4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20a60231-64f0-4751-aa81-6c0e64334179 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance. 12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6eb489d-2946-4c14-839f-d4af761ead31 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c62d424c-7630-413c-be2c-3932831c3f1d (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29bddc43-2809-4e1f-ae35-2865e15e9bb6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf2dca37-ce9c-40e4-8ad6-b8186aa7fed1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance. 12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ff464e6-7a36-4544-a06f-7848414f77fc (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance. 12.3 Pharmacokinetics Absorption: Following oral administration, peak concentrations (C max ) of telmisartan are reached in 0.5 to 1 hour after dosing.
Projected row 1472
- Medicine slug
- telmisartan
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 41
- Source count
- 41
- Agreement rate
- 1
- Recorded readings
500 liters
- Numeric value
- 500
- Unit
- L
- Source records
- 41
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 41 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a075633a-2a2a-4e88-8ede-b49a3920a16c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf8e95fa-d181-4b46-8609-497e14a73dc1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:57da6ef2-2e86-4e4d-90df-73a2a8cf97f6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:509cd338-24db-41d1-a115-9dc999170717 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e1a907a7-fad9-a860-8639-4c6136c85734 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9c22a318-d1f2-4788-9331-66fed71ebf38 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:830741dd-3f3c-4f8e-88c6-dc112166f477 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56a72ddf-c2a2-45ce-91b1-1fcfbff52c10 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4ae8694-2af4-4acb-8634-b40c1cb6fb41 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32489e86-0432-4d74-92f6-15e7450f52fa (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:beaaf383-730f-4411-b5e7-15c32b53a338 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaed12cd-5bfe-4c98-9afc-025ed86a294f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09d31eee-cd22-4918-a889-3eb4d2969525 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:77442f0b-b522-4b19-ac1f-f0ce8576f0be (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f13e0919-5ee2-4855-b7c8-c8ab423769dd (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3658bc8-1524-43db-930e-66f9ac01b808 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e61c209a-4fc3-4f5c-b526-6412f0b8897c (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:44e810d4-cf04-41d3-bdf8-0681210a669f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:671d5a85-4146-43b4-9d7d-ca53268eb2a6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4be6575f-ea8d-4cd8-a49d-3d1c93f2621a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f021f06-99df-48d1-e063-6394a90a8d0f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6da5155-9c26-46bb-bc0f-ece4ea21405f (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:91215664-6e19-4e04-9ae7-ab5664799426 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d45da80a-58c3-4461-adf6-a85531c09eb8 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5ded796-3555-4476-8b37-0cdc88d7594a (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:353fcb30-2fa7-4ff1-8a18-26f3ec279d00 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fef6532d-438a-435e-a61f-216dd8551339 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:963e9245-ec7a-4bf6-9fc0-80f54e3657f0 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c55e4fe1-f04d-4995-a706-9f432fde57e4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5743c58e-deab-ac93-e063-6294a90ac1eb (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e2deff49-b75e-4aaa-8114-d5ea1e3a94a5 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd2b0604-f887-40d9-9109-dafcc9987e4e (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a020e2a7-d1e7-8ae0-e053-2995a90abad3 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71902893-55da-4286-8b25-b528641489ef (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:593a53a4-91bc-4e4a-aeff-08fc2efe3dd4 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20a60231-64f0-4751-aa81-6c0e64334179 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c6eb489d-2946-4c14-839f-d4af761ead31 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c62d424c-7630-413c-be2c-3932831c3f1d (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:29bddc43-2809-4e1f-ae35-2865e15e9bb6 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bf2dca37-ce9c-40e4-8ad6-b8186aa7fed1 (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3ff464e6-7a36-4544-a06f-7848414f77fc (opens source in a new tab)
Telmisartan label
Version not recorded · Effective date not recorded
The volume of distribution for telmisartan is approximately 500 liters indicating additional tissue binding.
Projected row 1473
- Medicine slug
- telotristat-ethyl
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
0.6 hours
- Numeric value
- 0.6
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9108ac3-ca6e-4faf-9d04-953abb64d072 (opens source in a new tab)
Telotristat Ethyl label
Version not recorded · Effective date not recorded
Elimination Following a single 500 mg oral dose of telotristat ethyl in healthy subjects, the apparent half-life was approximately 0.6 hours for telotristat ethyl and 5 hours for telotristat.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4ac9d62-887c-4c8f-b04d-a5f31cec7c86 (opens source in a new tab)
Telotristat Ethyl label
Version not recorded · Effective date not recorded
Elimination Following a single 500 mg oral dose of telotristat ethyl in healthy subjects, the apparent half-life was approximately 0.6 hours for telotristat ethyl and 5 hours for telotristat.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f11c21f8-f725-445e-b38e-1e4c5b05bcc6 (opens source in a new tab)
Telotristat Ethyl label
Version not recorded · Effective date not recorded
Elimination Following a single 500 mg oral dose of telotristat ethyl in healthy subjects, the apparent half-life was approximately 0.6 hours for telotristat ethyl and 5 hours for telotristat.
Projected row 1474
- Medicine slug
- telotristat-ethyl
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
0.5 to 2 hours
- Numeric value
- 0.5
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f9108ac3-ca6e-4faf-9d04-953abb64d072 (opens source in a new tab)
Telotristat Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of telotristat ethyl were achieved within 0.5 to 2 hours, and those of telotristat within 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a4ac9d62-887c-4c8f-b04d-a5f31cec7c86 (opens source in a new tab)
Telotristat Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of telotristat ethyl were achieved within 0.5 to 2 hours, and those of telotristat within 1 to 3 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f11c21f8-f725-445e-b38e-1e4c5b05bcc6 (opens source in a new tab)
Telotristat Ethyl label
Version not recorded · Effective date not recorded
Peak plasma concentrations of telotristat ethyl were achieved within 0.5 to 2 hours, and those of telotristat within 1 to 3 hours.
Projected row 1475
- Medicine slug
- temozolomide
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 20
- Source count
- 20
- Agreement rate
- 1
- Recorded readings
1.8 hours
- Numeric value
- 1.8
- Unit
- hours
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70996a9d-4a4f-4ed1-ab07-130486aa14ab (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33d67bce-38ae-45fc-a858-d51167b0ecfd (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is about 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b263fe0-5f06-4889-bf14-4aa185470810 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021b97cc-a76f-44b6-b7be-670d2ae83690 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6d762ea-fff0-43e8-b67d-bef19e883dd8 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56245d21-4a42-471e-bbdc-80b129336e2f (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f17780-8037-44a0-9e84-b7150c9bde12 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a147b361-262c-49c6-9b8e-7e454f755721 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79766855-2533-43b1-b60e-1e9daecadad5 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c8529ec-8936-4fec-a1a5-2b285c7e4859 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eb0bd33-582f-43a6-a607-e72b4390c6d3 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0f2077c-48e6-452e-9f88-e1f2c89df0a2 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f743f7e0-74cf-47e5-bf21-f2b75d2596dc (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78c12889-c837-40c1-8f85-4d048008ad29 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:046a9011-3911-4d3f-a15f-fbb56d5aad56 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d599ccf-8e63-4ff1-aa52-4809744ea97a (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1e05c21-a411-4493-80de-ede373632475 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dff10ec-6a55-47b6-a458-b7c39e32dc55 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3f69c67-db30-4266-8075-9b18c71c9fc1 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is approximately 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27e5a781-e4f2-4489-9def-7971d0b86d9c (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Elimination Clearance of temozolomide is about 5.5 L/hr/m 2 and the mean elimination half-life is 1.8 hours.
Projected row 1476
- Medicine slug
- temozolomide
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 20
- Source count
- 20
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70996a9d-4a4f-4ed1-ab07-130486aa14ab (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33d67bce-38ae-45fc-a858-d51167b0ecfd (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median Tmax is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b263fe0-5f06-4889-bf14-4aa185470810 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021b97cc-a76f-44b6-b7be-670d2ae83690 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6d762ea-fff0-43e8-b67d-bef19e883dd8 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56245d21-4a42-471e-bbdc-80b129336e2f (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f17780-8037-44a0-9e84-b7150c9bde12 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a147b361-262c-49c6-9b8e-7e454f755721 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79766855-2533-43b1-b60e-1e9daecadad5 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c8529ec-8936-4fec-a1a5-2b285c7e4859 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eb0bd33-582f-43a6-a607-e72b4390c6d3 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0f2077c-48e6-452e-9f88-e1f2c89df0a2 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f743f7e0-74cf-47e5-bf21-f2b75d2596dc (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78c12889-c837-40c1-8f85-4d048008ad29 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:046a9011-3911-4d3f-a15f-fbb56d5aad56 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d599ccf-8e63-4ff1-aa52-4809744ea97a (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1e05c21-a411-4493-80de-ede373632475 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dff10ec-6a55-47b6-a458-b7c39e32dc55 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3f69c67-db30-4266-8075-9b18c71c9fc1 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27e5a781-e4f2-4489-9def-7971d0b86d9c (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Absorption The median T max is 1 hour.
Projected row 1477
- Medicine slug
- temozolomide
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 20
- Source count
- 20
- Agreement rate
- 1
- Recorded readings
0.4 L/kg
- Numeric value
- 0.4
- Unit
- L/kg
- Source records
- 20
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 20 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70996a9d-4a4f-4ed1-ab07-130486aa14ab (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33d67bce-38ae-45fc-a858-d51167b0ecfd (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean apparent volume of distribution of 0.4 L/kg (%CV = 13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6b263fe0-5f06-4889-bf14-4aa185470810 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:021b97cc-a76f-44b6-b7be-670d2ae83690 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6d762ea-fff0-43e8-b67d-bef19e883dd8 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56245d21-4a42-471e-bbdc-80b129336e2f (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f17780-8037-44a0-9e84-b7150c9bde12 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a147b361-262c-49c6-9b8e-7e454f755721 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:79766855-2533-43b1-b60e-1e9daecadad5 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c8529ec-8936-4fec-a1a5-2b285c7e4859 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6eb0bd33-582f-43a6-a607-e72b4390c6d3 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c0f2077c-48e6-452e-9f88-e1f2c89df0a2 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f743f7e0-74cf-47e5-bf21-f2b75d2596dc (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:78c12889-c837-40c1-8f85-4d048008ad29 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:046a9011-3911-4d3f-a15f-fbb56d5aad56 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2d599ccf-8e63-4ff1-aa52-4809744ea97a (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1e05c21-a411-4493-80de-ede373632475 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9dff10ec-6a55-47b6-a458-b7c39e32dc55 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b3f69c67-db30-4266-8075-9b18c71c9fc1 (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean (CV%) apparent volume of distribution of 0.4 L/kg (13%).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27e5a781-e4f2-4489-9def-7971d0b86d9c (opens source in a new tab)
Temozolomide label
Version not recorded · Effective date not recorded
Distribution Temozolomide has a mean apparent volume of distribution of 0.4 L/kg (%CV=13%).
Projected row 1478
- Medicine slug
- tenapanor
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2102da5f-a1a0-4ac7-a1f6-38698cf7273a (opens source in a new tab)
Tenapanor label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of tenapanor and its major metabolite, M1, is approximately 99% and 97%, respectively, in vitro.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c57e279c-0f1b-4238-81b7-4e0dc0cc60c5 (opens source in a new tab)
Tenapanor label
Version not recorded · Effective date not recorded
Distribution Plasma protein binding of tenapanor and its major metabolite, M1, is approximately 99% and 97%, respectively , in vitro.
Projected row 1479
- Medicine slug
- tenofovir-disoproxil
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 18
- Source count
- 18
- Agreement rate
- 0.944444
- Recorded readings
40%
- Numeric value
- 40
- Unit
- %
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e0e1b7-6a45-4d63-b569-00826832c25a (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0 to ∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08a30772-02fc-4f63-e063-6394a90afd43 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0 to ∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c7d72d6-bf80-49e0-921c-20169e87e62f (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0– ∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3285f345-e58d-4831-a6a8-31094c8c546d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0– ∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de27413a-6579-4586-80dc-39c712652952 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0-∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcd3120b-60f6-41d8-a512-ed4a62c836b4 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0-∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0ae0aa2-3baa-4b75-9e85-68b5338c3c14 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0– ∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:532755cb-1cd3-4774-97af-05a53779b65f (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0-∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a75c6be8-3719-4bb3-8a9e-06e5254d2a82 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0–∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f0bc342-0a0a-1d28-e053-2991aa0a28b9 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0 to ∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaeb1670-4e39-4541-8ff7-47057f3f5c36 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0 to ∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ac4c628-f01f-42d4-b8e6-d12273aefc6d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC0 to ∞ of approximately 40% and an increase in Cmax of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9cf11bd3-01b9-4ac8-96cc-55d57998b51d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
E ffects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0-∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18285dda-d63f-4f0e-821f-a4f2df335c35 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC0 to ∞ of approximately 40% and an increase in Cmax of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92569e53-507e-7a5b-e053-2995a90aca35 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0– ∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da78a5d3-f5c6-47fe-b593-3252704c225d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1,000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0-∞ of approximately 40% and an increase in C max of approximately 14%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a215f64c-84de-0649-e053-2a95a90a9d59 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Effects of Food on Oral Absorption Administration of tenofovir disoproxil fumarate 300 mg tablets following a high-fat meal (~700 to 1000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC 0-∞ of approximately 40% and an increase in C max of approximately 14%.
25%
- Numeric value
- 25
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33fd6418-fbdc-42ca-a50d-ce2a476a5418 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
The oral bioavailability of tenofovir from VIREAD in fasted subjects is approximately 25%.
Projected row 1480
- Medicine slug
- tenofovir-disoproxil
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 18
- Source count
- 18
- Agreement rate
- 1
- Recorded readings
17 hours
- Numeric value
- 17
- Unit
- hours
- Source records
- 18
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 18 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:67e0e1b7-6a45-4d63-b569-00826832c25a (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate tablets, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08a30772-02fc-4f63-e063-6394a90afd43 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate tablets, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c7d72d6-bf80-49e0-921c-20169e87e62f (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3285f345-e58d-4831-a6a8-31094c8c546d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de27413a-6579-4586-80dc-39c712652952 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bcd3120b-60f6-41d8-a512-ed4a62c836b4 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e0ae0aa2-3baa-4b75-9e85-68b5338c3c14 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:532755cb-1cd3-4774-97af-05a53779b65f (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a75c6be8-3719-4bb3-8a9e-06e5254d2a82 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7f0bc342-0a0a-1d28-e053-2991aa0a28b9 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate tablets, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eaeb1670-4e39-4541-8ff7-47057f3f5c36 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate tablets, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ac4c628-f01f-42d4-b8e6-d12273aefc6d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:33fd6418-fbdc-42ca-a50d-ce2a476a5418 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of VIREAD, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9cf11bd3-01b9-4ac8-96cc-55d57998b51d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate tablet, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:18285dda-d63f-4f0e-821f-a4f2df335c35 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92569e53-507e-7a5b-e053-2995a90aca35 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da78a5d3-f5c6-47fe-b593-3252704c225d (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a215f64c-84de-0649-e053-2a95a90a9d59 (opens source in a new tab)
Tenofovir Disoproxil label
Version not recorded · Effective date not recorded
Following single dose, oral administration of tenofovir disoproxil fumarate, the terminal elimination half-life of tenofovir is approximately 17 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1470Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.